ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment

This study has been completed.

Sponsors and Collaborators: Institut Bergonié
Sanofi-Synthelabo
Aventis Pharmaceuticals
Amgen
Chugai Pharmaceutical
Bristol-Myers Squibb
Information provided by: Institut Bergonié
ClinicalTrials.gov Identifier: NCT00210249
  Purpose

Number of elderly people over 70 is increasing in France. In 2002, in the south-west, 273,741 of them were over 75 years, i.e. 9.2% of Aquitaine population. Incidence of cancer in this old age is 16,500 new cases per year, more than fifty percent of people with cancer. Treatment modalities of elderly people is one of the 70 priorities of the "Plan cancer" instituted by the French government. They are very few therapeutic trials dedicated. Oncologists hesitate to treat them because they are either afraid of inducing toxicity or of breaking down quality of life. Consequently, we decided to launch a protocol with both oncologists and geriatricians which principal aim is to find out if geriatric assessment data can help to better predict for chemotherapy toxicity, loss of autonomy and survival. We plan to accrue 360 patients diagnosed for cancer, including digestive, pulmonary, prostate, lymphoma, bladder, ovary cancer for whom first-line chemotherapy is planned. Patients are initially classified according to usual methods of medical oncology practice into three groups: patients who can receive standard treatment, reduced standard treatment or treatment adapted to the frail condition. Around Aquitaine, , we organised seven teams composed of one geriatrician and one nurse. Two kind of teams were activated: one which cover ten treatment sites in Bordeaux area and six sedentary teams which worked half a day a week in designated hospitals . Geriatric evaluation included test of cognitive functions (MMS), nutritional status (MNA), co-morbidity (CIRS-G), mobility (Get up and Go), activities (ADL;IADL), quality of life (QLQ-C30), depression (GDS-15) and Lachs-Balducci screening. Patients have four geriatric evaluations : before treatment, day 1 cycle 2, day 1 cycle 4, day 1 cycle 7 and/or end of chemotherapy. Since September 2002, 177 patients have been included, 112 have finished: 47.3% have received four evaluations, 16.1% died before the end of protocol, 14.3% stopped because they were in progression and changed their treatment, 11.6% met administrative problem that didn't allow all evaluations, 7.1% declined after inclusion and 3.6% finished their treatment before. The following results have been obtained: before treatment, 73% of these patients were at risk of undernutrition (MNA< 23.5), about 1/3 had one or more inability or a risk of falls (38% IADL<6, 29% get up and go>20seconds, 27% ADL>1, 34% PS<1), 28% of them had altered cognitive functions (MMS<24), 29% were depressive (GDS-15>6), 25% thought they had poor quality of life (QLQ-C30<4). Protocol will be closed in September 2005.


Condition
Lymphoma
Digestive System Diseases
Ovarian Diseases
Pulmonary Disease
Prostatic Disease
Bladder Disease

MedlinePlus related topics:   Bladder Diseases    Cancer    Digestive Diseases    Lymphoma    Prostate Diseases   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Prospective
Official Title:   Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country.

Further study details as provided by Institut Bergonié:

Estimated Enrollment:   360
Study Start Date:   September 2002
Study Completion Date:   June 2006

  Eligibility
Ages Eligible for Study:   70 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion criteria:

  • Age ≥ 70 years
  • First line of chemotherapy
  • Cancer previously mentioned
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00210249

Locations
France
Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest    
      Bordeaux, France, 33076
Centre de radiothérapie d'Agen    
      Agen, France, 47000
Centre Hospitalier Universitaire d'Agen    
      AGEN, France, 47000
Centre Hospitalier Universitaire de Bordeaux    
      Bordeaux, France, 33076
Centre Hospitalier Universitaire de Pau    
      Pau, France, 64000
Centre Hospitalier Universitaire de Villeneuve sur Lot    
      Villeneuve sur Lot, France, 47000
Clinique Francheville    
      Perigueux, France, 24000
Clinique Tivoli    
      Bordeaux, France, 33000
Hopital Sub-Urbain du Bouscat    
      Le Bouscat, France, 33110
Centre Hospitalier Universitaire de Mont de Marsan    
      Mont de Marsan, France, 40000
Centre Hospitalier Universitaire de Bayonne    
      Bayonne, France, 64000
Centre Hospitalier Universitaire de Dax    
      Dax, France, 40100
Maison de Santé Protestante Bagatelle    
      Talence, France, 33400
Centre Hospitalier de la Côte Basque    
      Bayonne, France, 64100
Centre Hospitalier Universitaire de Perigueux    
      Perigueux, France, 24000
Clinique Esquirol Saint Hilaire    
      Agen, France, 47000
Clinique Saint Etienne du Pays Basque    
      Bayonne, France, 64100
Hôpital Robert Boulin    
      Libourne, France, 33500

Sponsors and Collaborators
Institut Bergonié
Sanofi-Synthelabo
Aventis Pharmaceuticals
Amgen
Chugai Pharmaceutical
Bristol-Myers Squibb

Investigators
Principal Investigator:     Pierre SOUBEYRAN, MD, PhD     Institut Bergonié    
  More Information


Study ID Numbers:   IB2002-26, ONCOGERIATRIE
First Received:   September 13, 2005
Last Updated:   October 31, 2007
ClinicalTrials.gov Identifier:   NCT00210249
Health Authority:   France: Afssaps - French Health Products Safety Agency

Keywords provided by Institut Bergonié:
Cancer  
elderly  
geriatric evaluation  
safety  
chemotherapy  

Study placed in the following topic categories:
Immunoproliferative Disorders
Prostatic Diseases
Gonadal Disorders
Urinary Bladder Diseases
Endocrine System Diseases
Ovarian Diseases
Genital Diseases, Male
Genital Diseases, Female
Lymphatic Diseases
Digestive System Diseases
Urologic Diseases
Respiratory Tract Diseases
Lung Diseases
Endocrinopathy
Lymphoproliferative Disorders
Lymphoma

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Histologic Type
Immune System Diseases
Adnexal Diseases

ClinicalTrials.gov processed this record on October 03, 2008




Links to all studies - primarily for crawlers